Clinical Trial Update: Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA [Phase 2, Phase 3]

View source ↗

Summary

Completed Phase 2 and Phase 3 clinical trial evaluating stem cell transplant for Dyskeratosis Congenita and Aplastic Anemia; results posted on 2017-05-31.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Dyskeratosis Congenita

Drugs mentioned

• Stem cell transplant

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Dyskeratosis Congenita, Aplastic Anemia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-05-31